Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

Oncogene

Volumn 24, Issue 40, 2005, Pages 6080-6089

  Altomare, Deborah A ^a   You, Huihong ^a   Xiao, Guang Hui ^a   Ramos Nino, Maria E ^b   Skele, Kristine L ^a   De Rienzo, Assunta ^a   Jhanwar, Suresh C ^c   Mossman, Brooke T ^b   Kane, Agnes B ^d   Testa, Joseph R ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

AKT; Asbestos; Mesothelioma; mTOR

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PROTEIN KINASE B; AKT1 PROTEIN, HUMAN; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE DELETION; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; GENE EXPRESSION PROFILING; MESOTHELIOMA; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALIA; MURINAE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME INDUCTION; GENE EXPRESSION PROFILING; HUMANS; MESOTHELIOMA; MICE; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 24944539840     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1208744     Document Type: Article

References (45)

1. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK and Testa JR. (2004). Oncogene, 23, 5853-5857.
2. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB and Polunovsky VA. (2004). Cancer Cell, 5, 553-563.
3. Bellacosa A, Kumar C, Di Cristofano A and Testa JR. Adv. Cancer Res. in press.
4. Bjornsti MA and Houghton PJ. (2004). Cancer Cell, 5, 519-523.
5. Boudeau J, Sapkota G and Alessi DR. (2003). FEBS Lett., 546, 159-165.
6. Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM and Laterra J. (2000). Cancer Res., 60, 4277-4283.
7. Britton M. (2002). Semin. Oncol., 29, 18-25.
8. Brognard J, Clark AS, Ni Y and Dennis PA. (2001). Cancer Res., 61, 3986-3997.
9. Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L and Gaudino G. (2001). Proc. Natl. Acad. Sci. USA, 98, 12032-12037.
10. Cao XX, Mohuiddin I, Ece F, McConkey DJ and Smythe WR. (2001). Am. J. Respir. Cell Mol. Biol., 25, 562-568.
11. Craighead JE and Mossman BT. (1982). New Engl. J. Med., 306, 1446-1455.
12. Di Cristofano A and Pandolfi PP. (2000). Cell, 100, 387-390.
13. Eng C. (2003). Hum. Mutat., 22, 183-198.
14. Goodglick LA, Vaslet CA, Messier NJ and Kane AB. (1997). Toxicol. Pathol., 25, 565-573.
15. Harvey P, Clark IM, Jaurand MC, Warn RM and Edwards DR. (2000). Br. J. Cancer, 83, 1147-1153.
16. Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB. (2002). Cancer Res., 62, 1087-1092.
17. Huang S and Houghton PJ. (2001). Drug Resistance Updates, 4, 378-391.
18. Klominek J, Baskin B, Liu Z and Hauzenberger D. (1998). Int. J. Cancer, 76, 240-249.
19. Kwiatkowski DJ. (2003). Ann. Hum. Genet., 67, 87-96.
20. Liu AX, Testa JR, Hamilton TC, Jove R, Nicosia SV and Cheng JQ. (1998). Cancer Res., 58, 2973-2977.
21. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA and Sellers WR. (2004). Nat. Med., 10, 594-601.
22. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M and Sellers WR. (2003). Proc. Natl. Acad. Sci. USA, 100, 7841-7846.
23. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW and Sonenberg N. (2004). Oncogene, 23, 3172-3179.
24. Manning BD and Cantley LC. (2003). Trends Biochem. Sci., 28, 573-576.
25. Nakatani K, Thompson D, Barthel A, Sakaue H, Liu W, Weigel RJ and Roth RA. (1999). J. Biol. Chem., 274, 21528-21532.
26. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H and Sawyers CL. (2001). Proc. Natl. Acad. Sci. USA, 98, 10031-10033.
27. Nowak AK, Lake RA, Kindler HL and Robinson BW. (2002). Semin. Oncol., 29, 82-96.
28. Papp T, Schipper H, Pemsel H, Unverricht M, Muller KM, Wiethege T, Schiffmann D and Rahman Q. (2001). Oncol Rep., 8, 1375-1379.
29. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ and Phillips WA. (2001). Cancer Res., 61, 7426-7429.
30. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L and Parsons R. (2001). Proc. Natl. Acad. Sci. USA, 98, 10320-10325.
31. Pullen N and Thomas G. (1997). FEBS Lett., 410, 78-82.
32. Rizzo P, Bocchetta M, Powers A, Foddis R, Stekala E, Pass HI and Carbone M. (2001). Semin. Cancer Biol., 11, 63-71.
33. Rusch VW. (2003). J. Clin. Oncol., 21, 2629-2630.
34. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE. (2004). Science, 304, 554.
35. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW. (1999). Nat. Genet., 21, 99-102.
36. Sonenberg N and Gingras AC. (1998). Curr. Opin. Cell Biol., 10, 268-275.
37. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM and Testa JR. (1993). Cancer Res., 53, 4349-4355.
38. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH and Testa JR. (2001). Cancer Res., 61, 589-593.
39. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B and Muller KM. (1998). J. Cancer Res. Clin. Oncol., 124, 291-296.
40. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P. (2003). J. Clin. Oncol., 21, 2636-2644.
41. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J and Lowe SW. (2004). Nature, 428, 332-337.
42. West KA, Sianna Castillo S and Dennis PA. (2002). Drug Resistance Updates, 5, 234-248.
43. Wu H, Goel V and Haluska FG. (2003). Oncogene, 22, 3113-3122.
44. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF and Testa JR. (2001). Proc. Natl. Acad. Sci. USA, 98, 247-252.
45. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV and Cheng JQ. (2000). Oncogene, 19, 2324-2330.